Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 13 |
| List of Tables | 12 | 2 |
| List of Figures | 14 | 1 |
| Introduction | 15 | 1 |
| Global Markets Direct Report Coverage | 15 | 1 |
| Dementia Overview | 16 | 1 |
| Therapeutics Development | 17 | 2 |
| Pipeline Products for Dementia Overview | 17 | 1 |
| Pipeline Products for Dementia Comparative Analysis | 18 | 1 |
| Dementia Therapeutics under Development by Companies | 19 | 3 |
| Dementia Therapeutics under Investigation by Universities/Institutes | 22 | 1 |
| Dementia Pipeline Products Glance | 23 | 4 |
| Late Stage Products | 23 | 1 |
| Clinical Stage Products | 24 | 1 |
| Early Stage Products | 25 | 1 |
| Unknown Stage Products | 26 | 1 |
| Dementia Products under Development by Companies | 27 | 4 |
| Dementia Products under Investigation by Universities/Institutes | 31 | 1 |
| Dementia Companies Involved in Therapeutics Development | 32 | 47 |
| Adamas Pharmaceuticals, Inc. | 32 | 1 |
| AgeneBio Inc. | 33 | 1 |
| Alector LLC | 34 | 1 |
| AlzProtect SAS | 35 | 1 |
| Amarantus Bioscience Holdings, Inc. | 36 | 1 |
| Anavex Life Sciences Corp. | 37 | 1 |
| Axon Neuroscience SE | 38 | 1 |
| Axovant Sciences Ltd. | 39 | 1 |
| BioArctic Neuroscience AB | 40 | 1 |
| Biogen Inc | 41 | 1 |
| Biotie Therapies Corp. | 42 | 1 |
| Boehringer Ingelheim GmbH | 43 | 1 |
| Chase Pharmaceuticals Corporation | 44 | 1 |
| Cortice Biosciences, Inc. | 45 | 1 |
| Daewoong Pharmaceutical Co., Ltd. | 46 | 1 |
| Eisai Co., Ltd. | 47 | 1 |
| Eli Lilly and Company | 48 | 1 |
| FORUM Pharmaceuticals Inc. | 49 | 1 |
| H. Lundbeck A/S | 50 | 1 |
| Heptares Therapeutics Limited | 51 | 1 |
| Hyundai Pharmaceutical Co., Ltd. | 52 | 1 |
| Ildong Pharmaceutical Co., Ltd. | 53 | 1 |
| Immungenetics AG | 54 | 1 |
| ImStar Therapeutics Inc. | 55 | 1 |
| Integrative Research Laboratories Sweden AB | 56 | 1 |
| Intellect Neurosciences, Inc. | 57 | 1 |
| Intra-Cellular Therapies, Inc. | 58 | 1 |
| INVENT Pharmaceuticals, Inc. | 59 | 1 |
| M3 Biotechnology, Inc. | 60 | 1 |
| MediPost Co., Ltd. | 61 | 1 |
| Neuraltus Pharmaceuticals, Inc. | 62 | 1 |
| Neurimmune Holding AG | 63 | 1 |
| Neurodyn Inc. | 64 | 1 |
| Oryzon Genomics SA | 65 | 1 |
| Otsuka Holdings Co., Ltd. | 66 | 1 |
| P2D Bioscience | 67 | 1 |
| Pacific Northwest Biotechnology, LLC | 68 | 1 |
| Pivot Pharmaceuticals Inc | 69 | 1 |
| Sinil Pharmaceutical Co., Ltd | 70 | 1 |
| Stelic Institute &Co., Inc. | 71 | 1 |
| Sumitomo Dainippon Pharma Co., Ltd. | 72 | 1 |
| Sylentis S.A.U. | 73 | 1 |
| Takeda Pharmaceutical Company Limited | 74 | 1 |
| TauRx Therapeutics Ltd. | 75 | 1 |
| Voyager Therapeutics, Inc. | 76 | 1 |
| WhanIn Pharmaceutical Co., Ltd. | 77 | 1 |
| Zhejiang Hisun Pharmaceutical Co., Ltd. | 78 | 1 |
| Dementia Therapeutics Assessment | 79 | 12 |
| Assessment by Monotherapy Products | 79 | 1 |
| Assessment by Combination Products | 80 | 1 |
| Assessment by Target | 81 | 3 |
| Assessment by Mechanism of Action | 84 | 3 |
| Assessment by Route of Administration | 87 | 2 |
| Assessment by Molecule Type | 89 | 2 |
| Drug Profiles | 91 | 121 |
| (donepezil hydrochloride + memantine hydrochloride ER) Drug Profile | 91 | 2 |
| (donepezil hydrochloride + solifenacin succinate) Drug Profile | 93 | 1 |
| AADvac-1 Drug Profile | 94 | 1 |
| AD-35 Drug Profile | 95 | 1 |
| ANAVEX-371 Drug Profile | 96 | 2 |
| Antisense RNAi Oligonucleotide for Cerebral Ischemia and Dementia Drug Profile | 98 | 1 |
| ASN-561 Drug Profile | 99 | 1 |
| AVP-786 Drug Profile | 100 | 3 |
| AZP-2006 Drug Profile | 103 | 2 |
| BAN-0805 Drug Profile | 105 | 1 |
| BI-409306 Drug Profile | 106 | 2 |
| CB-2233 Drug Profile | 108 | 1 |
| CB-8411 Drug Profile | 109 | 1 |
| choline alfoscerate SR Drug Profile | 110 | 1 |
| D-217 Drug Profile | 111 | 1 |
| dehydroevodiamine hydrochloride Drug Profile | 112 | 1 |
| Drugs for Dementia Drug Profile | 113 | 1 |
| Drugs to Agonize Hepatocyte Growth Factor Receptor for Dementia Drug Profile | 114 | 1 |
| Drugs to Inhibit Matrix Metalloproteinase for Dementia and Cognitive Impairment Drug Profile | 115 | 1 |
| DWJ-1365 Drug Profile | 116 | 1 |
| E-2609 Drug Profile | 117 | 2 |
| eltoprazine Drug Profile | 119 | 5 |
| encenicline hydrochloride Drug Profile | 124 | 5 |
| FRM-0334 Drug Profile | 129 | 2 |
| GIBH-130 Drug Profile | 131 | 1 |
| Gln-1062 Drug Profile | 132 | 3 |
| GTC-6000 Drug Profile | 135 | 1 |
| gugulipid Drug Profile | 136 | 1 |
| HOB-075 Drug Profile | 137 | 1 |
| HTL-18318 Drug Profile | 138 | 1 |
| intepirdine Drug Profile | 139 | 2 |
| INV-331 Drug Profile | 141 | 1 |
| IRL-752 Drug Profile | 142 | 1 |
| ITI-007 Drug Profile | 143 | 8 |
| levetiracetam Drug Profile | 151 | 2 |
| LUAF-20513 Drug Profile | 153 | 1 |
| MM-201 Drug Profile | 154 | 1 |
| Monoclonal Antibodies for Alzheimer s Disease and Vascular Dementia Drug Profile | 155 | 1 |
| Monoclonal Antibodies for Dementia and Alzheimer's Disease Drug Profile | 156 | 1 |
| Monoclonal Antibodies to Inhibit Tau for CNS Disorders Drug Profile | 157 | 1 |
| monosodium luminol Drug Profile | 158 | 2 |
| NAT Drug Profile | 160 | 1 |
| nelotanserin Drug Profile | 161 | 2 |
| Neurostem Drug Profile | 163 | 2 |
| NI-205 Drug Profile | 165 | 1 |
| NI-308 Drug Profile | 166 | 1 |
| NNC-269100 Drug Profile | 167 | 1 |
| NP-001 Drug Profile | 168 | 3 |
| ORY-2001 Drug Profile | 171 | 2 |
| P-003 Drug Profile | 173 | 1 |
| PD-2015 Drug Profile | 174 | 1 |
| PD-2016 Drug Profile | 175 | 1 |
| PD-2024 Drug Profile | 176 | 1 |
| PD-2244 Drug Profile | 177 | 1 |
| Peptide to Inhibit BACE for Cerebropathy and Dementia Drug Profile | 178 | 1 |
| PST-900 Drug Profile | 179 | 1 |
| salicylamine Drug Profile | 180 | 1 |
| SIN-1502 Drug Profile | 181 | 1 |
| Small Molecule for Dementia Drug Profile | 182 | 1 |
| Small Molecule to Activate ABC Transporter for Neurodegeneration Disorders Drug Profile | 183 | 1 |
| Small Molecule to Activate LPL for CNS and Metabolic Disorders Drug Profile | 184 | 1 |
| Small Molecule to Inhibit Glycogene 5 for Dementia Drug Profile | 185 | 1 |
| Small Molecules for Frontotemporal Dementia Drug Profile | 186 | 1 |
| Small Molecules for Ophthalmology and CNS Disorders Drug Profile | 187 | 1 |
| Small Molecules to Agonize HGFR for CNS Disorders Drug Profile | 188 | 1 |
| Small Molecules to Agonize M1 Muscarinic Acetylcholine Receptor for Lewy Body Dementia and Parkinson's Disease Dementia Drug Profile | 189 | 1 |
| Small Molecules to Inhibit TANA for ALS, Alzheimer's Disease and Dementia Drug Profile | 190 | 1 |
| SND-14 Drug Profile | 191 | 1 |
| SYN-120 Drug Profile | 192 | 2 |
| Synthetic Peptides to Activate PACAP Receptor and Antagonize VPAC1, VPAC2 for Neurological Disorders Drug Profile | 194 | 1 |
| TAK-070 Drug Profile | 195 | 1 |
| TAK-071 Drug Profile | 196 | 1 |
| TauC-3 Drug Profile | 197 | 1 |
| tolfenamic acid Drug Profile | 198 | 1 |
| TPI-287 Drug Profile | 199 | 4 |
| TRx-0237 Drug Profile | 203 | 4 |
| TTT-3002 Drug Profile | 207 | 1 |
| VYTAU-01 Drug Profile | 208 | 1 |
| WIB-1001C Drug Profile | 209 | 1 |
| zonisamide Drug Profile | 210 | 2 |
| Dementia Dormant Projects | 212 | 5 |
| Dementia Discontinued Products | 217 | 1 |
| Dementia Product Development Milestones | 218 | 14 |
| Featured News &Press Releases | 218 | 1 |
| Jul 27, 2016: Chase Pharmaceuticals Presents Phase 2 Results for CPC-201 at 2016 Alzheimer s Association International Conference | 218 | 1 |
| Jul 22, 2016: TauRx Phase 3 Trial TRx-237-007 in behavioural variant frontotemporal dementia | 219 | 1 |
| Jun 28, 2016: Intra-Cellular Therapies Announces Initiation of ITI-007-201 Phase 3 Clinical Trial for the Treatment of Agitation in Patients with Dementia, Including Alzheimer s Disease | 219 | 1 |
| Apr 21, 2016: FAU site for first US clinical trial for Lewy Body dementia | 220 | 1 |
| Apr 14, 2016: Aricept Approved in the Philippines for New Indication as Treatment for Dementia with Lewy Bodies | 221 | 1 |
| Apr 08, 2016: U.S. FDA Grants Orphan Drug Designation to ANAVEX 3-71 for the Treatment of Frontotemporal Dementia | 221 | 1 |
| Feb 25, 2016: Intra-Cellular Therapies Provides Product Update | 222 | 2 |
| Feb 17, 2016: AgeneBio to Present at Neuroscience BioPartnering &Investment Forum | 224 | 1 |
| Feb 09, 2016: Axovant Sciences Announces Launch Of First-In-Class Clinical Programs Of RVT-101 For Lewy Body Dementia | 224 | 2 |
| Feb 09, 2016: Axovant Sciences Announces Launch Of First-In-Class Clinical Programs Of Nelotanserin For Lewy Body Dementia | 226 | 1 |
| Dec 15, 2015: AgeneBio Launches New HOPE4MCI Phase 3 Clinical Trial Website | 227 | 1 |
| Dec 08, 2015: Amarantus Announces Positive Phase 2 Data for Eltoprazine in Alzheimer's Aggression | 227 | 2 |
| Nov 24, 2015: AgeneBio to Present at Future of Innovation in Medicine Conference | 229 | 1 |
| Oct 22, 2015: AgeneBio to Present at 8th Annual Clinical Trials on Alzheimer s Disease | 230 | 1 |
| Sep 15, 2015: NIH Awards $7.5 Million Grant for AgeneBio HOPE4MCI Phase 3 Clinical Trial to Delay the Onset of Alzheimer's Dementia | 230 | 2 |
| Appendix | 232 | 2 |
| Methodology | 232 | 1 |
| Coverage | 232 | 1 |
| Secondary Research | 232 | 1 |
| Primary Research | 232 | 1 |
| Expert Panel Validation | 232 | 1 |
| Contact Us | 232 | 1 |
| Disclaimer | 233 | 1 |